You are here

Vigabatrin Approved for Adult and Pediatric Epileptic Seizures

Adjunctive Therapy is First Generic Version of Sabril for Focal Seizures

The FDA has approved vigabatrin 500 mg tablets (Teva Pharmaceuticals USA) as an adjunctive therapy for complex partial seizures. The drug is indicated for treating focal seizures in patients aged 10 years and older who have responded inadequately to several alternative treatments.

Complex partial seizures begin in a specific part of the brain and can affect consciousness. They typically last between 30 and 90 seconds, and are often followed by disorientation, confusion, and/or fatigue.

Vigabatrin’s most common side effects include dizziness, fatigue, somnolence, involuntary eye movement, tremor, blurred vision, memory impairment, weight gain, arthralgia, upper respiratory tract infection, aggression, diplopia, abnormal coordination, and a confused state. Serious side effects include permanent vision loss and risk of suicidal thoughts or actions.

Source: PR Newswire, January 16, 2019

More Headlines

Policy Could Be Life-Changing for People With Spinal Cord Injury
Test Determines Severity of Pain, Helps Physicians Select Best Options
Intratumoral Injection Stimulates Immune Activation
Liver Fluke Infestation Affects Almost 2.5 Million People Globally
Diabetes and Cancer Patients Could Soon Avoid Injections
Early Cancer Development May Begin in Just 30 Minutes